Acquired mutations at this locus, which often arise as a result of BTK inhibition to treat chronic lymphocytic leukemia, result in constitutive downstream signaling and lymphocyte proliferation. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.